FitzGerald O, Ogdie A, Chandran V, Coates LC, Kavanaugh A, Tillett W, et al. Psoriatic arthritis. Nat Rev Dis Prim. 2021;7(1):59.

Article  PubMed  Google Scholar 

Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64(Suppl 2):ii14–7.

Sousa M, Lubrano E, Smolen JS, Gorlier C, de Wit M, Coates LC, et al. Patient-defined flares and disease activity worsening in 222 patients with psoriatic arthritis from 14 countries. Jt Bone Spine. 2023;90(3): 105511.

Article  Google Scholar 

Umezawa Y. Psoriatic arthritis. J Dermatol. 2021;48(6):741–9.

Article  PubMed  Google Scholar 

Van den Bosch F, Coates L. Clinical management of psoriatic arthritis. Lancet. 2018;391(10136):2285–94.

Article  PubMed  Google Scholar 

Tsuruta N, Imafuku S. Establishment of the Western Japan Psoriasis Registry and first cross-sectional analysis of registered patients. J Dermatol. 2021;48(11):1709–18.

Article  CAS  PubMed  Google Scholar 

Menter A, Papp KA, Gooderham M, Pariser DM, Augustin M, Kerdel FA, et al. Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Eur Acad Dermatol Venereol. 2016;30(7):1148–58.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cao Z, Carter C, Wilson KL, Schenkel B. Ustekinumab dosing, persistence, and discontinuation patterns in patients with moderate-to-severe psoriasis. J Dermatol Treat. 2015;26(2):113–20.

Article  CAS  Google Scholar 

Araujo EG, Finzel S, Englbrecht M, Schreiber DA, Faustini F, Hueber A, et al. High incidence of disease recurrence after discontinuation of disease-modifying antirheumatic drug treatment in patients with psoriatic arthritis in remission. Ann Rheum Dis. 2015;74(4):655–60.

Article  PubMed  Google Scholar 

Moverley A, Coates L, Marzo-Ortega H, Waxman R, Torgerson D, Cocks K, et al. A feasibility study for a randomised controlled trial of treatment withdrawal in psoriatic arthritis (REmoval of treatment for patients in REmission in psoriatic ArThritis (RETREAT (F)). Clin Rheumatol. 2015;34(8):1407–12.

Article  PubMed  Google Scholar 

Costa L, Perricone C, Chimenti MS, Del Puente A, Caso P, Peluso R, et al. Switching between biological treatments in psoriatic arthritis: a review of the evidence. Drugs R&D. 2017;17(4):509–22.

Article  CAS  Google Scholar 

Merola JF, Lockshin B, Mody EA. Switching biologics in the treatment of psoriatic arthritis. Semin Arthritis Rheum. 2017;47(1):29–37.

Article  PubMed  Google Scholar 

Gossec L, Siebert S, Bergmans P, de Vlam K, Gremese E, Joven-Ibáñez B, et al. Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world study. Ann Rheum Dis. 2023;82(4):496–506.

Article  CAS  PubMed  Google Scholar 

Inui K, Sato M, Esterberg E, Parikh RC, Kimura S, Torisu-Itakura H. Treatment practices and costs among patients with psoriatic arthritis: a Japanese hospital claims database analysis. Mod Rheumatol. 2021;31(6):1179–91.

Article  CAS  PubMed  Google Scholar 

Ballegaard C, Hojgaard P, Dreyer L, Cordtz R, Jorgensen TS, Skougaard M, et al. Impact of comorbidities on tumor necrosis factor inhibitor therapy in psoriatic arthritis: a population-based cohort study. Arthritis Care Res. 2018;70(4):592–9.

Article  CAS  Google Scholar 

Bayaraa B, Imafuku S. Sustainability and switching of biologics for psoriasis and psoriatic arthritis at Fukuoka University Psoriasis Registry. J Dermatol. 2019;46(5):389–98.

Article  CAS  PubMed  Google Scholar 

Wang C, Torisu-Itakura H, Hanada T, Matsuo T, Cai Z, Osaga S, et al. Treatment persistence of interleukin-17 inhibitor class drugs among patients with psoriasis in Japan: a retrospective database study. J Dermatol Treat. 2023;34(1):2229465.

Article  Google Scholar 

Kiltz U, Sfikakis PP, Gaffney K, Bounas A, Gullick N, Lespessailles E, et al. Interim 2-year analysis from SERENA: a real-world study in patients with psoriatic arthritis or ankylosing spondylitis treated with secukinumab. Rheumatol Ther. 2022;9(4):1129–42.

Article  PubMed  PubMed Central  Google Scholar 

Nakamura M. Utilization of MDV data and data quality control. Jpn J Pharmacoepidemiol. 2016;21(1):23–5.

Google Scholar 

Zhang H, Wen J, Alexander GC, Curtis JR. Comparative effectiveness of biologics and targeted therapies for psoriatic arthritis. RMD Open. 2021;7(1).

Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf. 2006;15(8):565–74 (discussion 75–7).

Granger E, Watkins T, Sergeant JC, Lunt M. A review of the use of propensity score diagnostics in papers published in high-ranking medical journals. BMC Med Res Methodol. 2020;20(1):132.

Article  PubMed  PubMed Central  Google Scholar 

Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41–55.

Article  Google Scholar 

Stuart EA. Matching methods for causal inference: a review and a look forward. Stat Sci. 2010;25(1):1–21.

Article  PubMed  PubMed Central  Google Scholar 

Haddad A, Gazitt T, Feldhamer I, Feld J, Cohen AD, Lavi I, et al. Treatment persistence of biologics among patients with psoriatic arthritis. Arthritis Res Ther. 2021;23(1):44.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alegre-Sancho JJ, Núñez-Monje V, Campos-Fernández C, Balaguer-Trull I, Robustillo-Villarino M, Aguilar-Zamora M, et al. Real-world effectiveness and persistence of secukinumab in the treatment of patients with psoriatic arthritis. Front Med. 2023;10:1294247.

Article  Google Scholar 

Joven B, Manteca CF, Rubio E, Raya E, Pérez A, Hernández R, et al. Real-world persistence and treatment patterns in patients with psoriatic arthritis treated with anti-IL17 therapy in Spain: the PerfIL-17 Study. Adv Ther. 2023;40(12):5415–31.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Perrone V, Losi S, Filippi E, Mezzetti M, Dovizio M, Sangiorgi D, et al. Analysis of the pharmacoutilization of biological drugs in psoriatic arthritis patients: a real-world retrospective study among an Italian population. Rheumatol Ther. 2022;9(3):875–90.

Article  PubMed  PubMed Central  Google Scholar 

Oelke KR, Chambenoit O, Majjhoo AQ, Gray S, Higgins K, Hur P. Persistence and adherence of biologics in US patients with psoriatic arthritis: analyses from a claims database. J Comp Effect Res. 2019;8(8):607–21.

Article  Google Scholar 

Ruscitti P, Pantano I, Perrotta FM, Celletti E, Volpe P, Ciliento MS, et al. The assessment of the drug retention rate of secukinumab in patients with psoriatic arthritis in a real-life multicentre cohort. Clin Exp Rheumatol. 2024;42(1):69–76.

PubMed  Google Scholar 

Tada Y, Morita A, Yamanaka K, Kono M, Imafuku S, Okubo Y, et al. Real-world retention rates and effectiveness of secukinumab in psoriasis: results from a multicenter cohort study (RAILWAY). J Dermatol. 2023;50(11):1415–26.

Article  CAS  PubMed  Google Scholar 

Sruamsiri R, Iwasaki K, Tang W, Mahlich J. Persistence rates and medical costs of biological therapies for psoriasis treatment in Japan: a real-world data study using a claims database. BMC Dermatol. 2018;18(1):5.

Article  PubMed  PubMed Central  Google Scholar 

Oh S, Choi S, Yoon HS. Available alternative biologics and disease groups influence biologic drug survival in patients with psoriasis and psoriatic arthritis. Ann Dermatol. 2022;34(5):321–30.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yiu ZZN, Becher G, Kirby B, Laws P, Reynolds NJ, Smith CH, et al. Drug survival associated with effectiveness and safety of treatment with guselkumab, ixekizumab, secukinumab, ustekinumab, and adalimumab in patients with psoriasis. JAMA Dermatol. 2022;158(10):1131–41.

Article  PubMed  PubMed Central  Google Scholar 

McInnes IB, Behrens F, Mease PJ, Kavanaugh A, Ritchlin C, Nash P, et al. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. Lancet. 2020;395(10235):1496–505.

Article  CAS  PubMed  Google Scholar 

Geale K, Lindberg I, Paulsson EC, Wennerström ECM, Tjärnlund A, Noel W, et al. Persistence of biologic treatments in psoriatic arthritis: a population-based study in Sweden. Rheumatol Adv Pract. 2020;4(2):rkaa070.